Development of a HT-ATACseq assay to identify epigenetic regulators of Ewing Sarcoma cancer cells (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

开发 HT-ATACseq 测定法来鉴定尤文肉瘤癌细胞的表观遗传调节因子（化学生物学联盟/NCI 实验治疗合作组织）

• 批准号: 10916055
• 负责人: Mark Henderson
• 金额: $ 12.58万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10916055
• 关键词: Biological Assay; Biology; Cells; Chemicals; Chromatin; Collaborations; DNA; Development; Enzymes; Epigenetic Process; Ewings sarcoma; Goals; Investigational Therapies; Measures; National Center for Advancing Translational Sciences; Pattern; Preparation; Research; cancer cell; cost; cost effective; high throughput screening; small molecule; small molecule libraries

During this period, the project team has completed optimization of experimental conditions of a high-throughput screening platform capable of measuring dynamic states of chromatin accessibility in cells using an enzyme-based approach (Assay for Transpose-Accessible Chromatin (ATAC)). The group has validated a crude preparation approach for the ATAC DNA that saves significant cost and increases throughput. Using the optimized assay, a pilot screen was performed using an epigenetic-focused small molecule library, and active compounds are undergoing further characterization.

在此期间，该项目团队完成了高通量筛选平台实验条件的优化，该平台能够使用基于酶的方法测量细胞中染色质可及性的动态状态（反式染色质测定（ATAC））。该小组已经验证了ATAC DNA的粗制备方法，该方法节省了大量成本并提高了通量。使用优化的测定，使用表观遗传学聚焦的小分子文库进行中试筛选，活性化合物正在进行进一步表征。